Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity.

Humbert N, Kovalenko L, Saladini F, Giannini A, Pires M, Botzanowski T, Cherenok S, Boudier C, Sharma KK, Real E, Zaporozhets OA, Cianférani S, Seguin-Devaux C, Poggialini F, Botta M, Zazzi M, Kalchenko VI, Mori M, Mély Y.

ACS Infect Dis. 2020 Feb 21. doi: 10.1021/acsinfecdis.9b00290. [Epub ahead of print]

PMID:
32045204
2.

Less Cytotoxic Protoflavones as Antiviral Agents: Protoapigenone 1'-O-isopropyl ether Shows Improved Selectivity Against the Epstein-Barr Virus Lytic Cycle.

Vágvölgyi M, Girst G, Kúsz N, Ötvös SB, Fülöp F, Hohmann J, Servais JY, Seguin-Devaux C, Chang FR, Chen MS, Chang LK, Hunyadi A.

Int J Mol Sci. 2019 Dec 12;20(24). pii: E6269. doi: 10.3390/ijms20246269.

3.

Predominance of the heterozygous CCR5 delta-24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface.

Arendt V, Amand M, Iserentant G, Lemaire M, Masquelier C, Ndayisaba GF, Verhofstede C, Karita E, Allen S, Chevigné A, Schmit JC, Bercoff DP, Seguin-Devaux C.

J Int AIDS Soc. 2019 Sep;22(9):e25384. doi: 10.1002/jia2.25384.

4.

FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Seguin-Devaux C, Plesseria JM, Verschueren C, Masquelier C, Iserentant G, Fullana M, Józsi M, Cohen JHM, Dervillez X.

Mol Oncol. 2019 Dec;13(12):2531-2553. doi: 10.1002/1878-0261.12554. Epub 2019 Sep 30.

5.

Injection of cocaine is associated with a recent HIV outbreak in people who inject drugs in Luxembourg.

Arendt V, Guillorit L, Origer A, Sauvageot N, Vaillant M, Fischer A, Goedertz H, François JH, Alexiev I, Staub T, Seguin-Devaux C.

PLoS One. 2019 May 16;14(5):e0215570. doi: 10.1371/journal.pone.0215570. eCollection 2019.

6.

Multicenter evaluation of the cobas® HIV-1 quantitative nucleic acid test for use on the cobas® 4800 system for the quantification of HIV-1 plasma viral load.

Adams P, Vancutsem E, Nicolaizeau C, Servais JY, Piérard D, François JH, Schneider T, Paxinos EE, Marins EG, Canchola JA, Seguin-Devaux C.

J Clin Virol. 2019 May;114:43-49. doi: 10.1016/j.jcv.2019.03.008. Epub 2019 Mar 16.

PMID:
30991164
7.

Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium.

Vinken L, Fransen K, Cuypers L, Alexiev I, Balotta C, Debaisieux L, Seguin-Devaux C, García Ribas S, Gomes P, Incardona F, Kaiser R, Ruelle J, Sayan M, Paraschiv S, Paredes R, Peeters M, Sönnerborg A, Vancutsem E, Vandamme AM, Van den Wijngaert S, Van Ranst M, Verhofstede C, Stadler T, Lemey P, Van Laethem K.

Front Microbiol. 2019 Mar 26;10:613. doi: 10.3389/fmicb.2019.00613. eCollection 2019.

8.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
9.

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C.

Popping S, Cento V, García F, Ceccherini-Silberstein F, Seguin-Devaux C, Vijver DA, Boucher CA.

J Virus Erad. 2018 Jul 1;4(3):179-181.

10.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

11.

Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients.

Belkhir L, Seguin-Devaux C, Elens L, Pauly C, Gengler N, Schneider S, Ruelle J, Haufroid V, Vandercam B.

Sci Rep. 2018 May 9;8(1):7359. doi: 10.1038/s41598-018-25803-z.

12.

Development of Mimokines, chemokine N terminus-based CXCR4 inhibitors optimized by phage display and rational design.

Fievez V, Szpakowska M, Mosbah A, Arumugam K, Mathu J, Counson M, Beaupain N, Seguin-Devaux C, Deroo S, Baudy-Floc'h M, Chevigné A.

J Leukoc Biol. 2018 Aug;104(2):343-357. doi: 10.1002/JLB.3MA0118-007. Epub 2018 Mar 23.

PMID:
29570832
13.

Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.

Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, Foster GR, Gheorghe L, Goldberg D, Goulis I, Hickman M, Hoffmann P, Jancorienė L, Jarcuska P, Kåberg M, Kostrikis LG, Makara M, Maimets M, Marinho RT, Matičič M, Norris S, Ólafsson S, Øvrehus A, Pawlotsky JM, Pocock J, Robaeys G, Roncero C, Simonova M, Sperl J, Tait M, Tolmane I, Tomaselli S, van der Valk M, Vince A, Dore GJ, Lazarus JV, Grebely J; International Network on Hepatitis in Substance Users (INHSU).

Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133. doi: 10.1016/S2468-1253(17)30284-4. Epub 2017 Oct 3.

PMID:
28986139
14.

Human CD56dimCD16dim Cells As an Individualized Natural Killer Cell Subset.

Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, Sauvageot N, Michel T, Aouali N, Janji B, Trujillo-Vargas CM, Seguin-Devaux C, Zimmer J.

Front Immunol. 2017 Jun 19;8:699. doi: 10.3389/fimmu.2017.00699. eCollection 2017.

15.

Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.

Amani-Bosse C, Dahourou DL, Malateste K, Amorissani-Folquet M, Coulibaly M, Dattez S, Emieme A, Barry M, Rouzioux C, N'gbeche S, Yonaba C, Timité-Konan M, Mea V, Ouédraogo S, Blanche S, Meda N, Seguin-Devaux C, Leroy V.

J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362.

16.

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.

Dahourou DL, Amorissani-Folquet M, Malateste K, Amani-Bosse C, Coulibaly M, Seguin-Devaux C, Toni T, Ouédraogo R, Blanche S, Yonaba C, Eboua F, Lepage P, Avit D, Ouédraogo S, Van de Perre P, N'Gbeche S, Kalmogho A, Salamon R, Meda N, Timité-Konan M, Leroy V; MONOD Study Group.

BMC Med. 2017 Apr 24;15(1):85. doi: 10.1186/s12916-017-0842-4.

17.

The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission.

Santos da Silva E, Mulinge M, Lemaire M, Masquelier C, Beraud C, Rybicki A, Servais JY, Iserentant G, Schmit JC, Seguin-Devaux C, Perez Bercoff D.

PLoS One. 2016 Sep 6;11(9):e0161596. doi: 10.1371/journal.pone.0161596. eCollection 2016.

18.

Improved Sensitivity of a Dual-Target HIV-1 Qualitative Test for Plasma and Dried Blood Spots.

Templer SP, Seiverth B, Baum P, Stevens W, Seguin-Devaux C, Carmona S.

J Clin Microbiol. 2016 Jul;54(7):1877-1882. doi: 10.1128/JCM.00128-16. Epub 2016 May 18.

19.

A microfluidics-based in vitro model of the gastrointestinal human-microbe interface.

Shah P, Fritz JV, Glaab E, Desai MS, Greenhalgh K, Frachet A, Niegowska M, Estes M, Jäger C, Seguin-Devaux C, Zenhausern F, Wilmes P.

Nat Commun. 2016 May 11;7:11535. doi: 10.1038/ncomms11535.

20.

Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller.

Chevigne A, Delhalle S, Counson M, Beaupain N, Rybicki A, Verschueren C, Staub T, Schmit JC, Seguin-Devaux C, Deroo S.

AIDS. 2016 Jan 28;30(3):377-82. doi: 10.1097/QAD.0000000000000925.

PMID:
26760231
21.

Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate.

Dauwe K, Mortier V, Schauvliege M, Van Den Heuvel A, Fransen K, Servais JY, Bercoff DP, Seguin-Devaux C, Verhofstede C.

BMC Infect Dis. 2015 Nov 16;15:524. doi: 10.1186/s12879-015-1217-0.

22.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
23.

Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg.

Struck D, Roman F, De Landtsheer S, Servais JY, Lambert C, Masquelier C, Venard V, Ruelle J, Nijhuis M, Schmit JC, Seguin-Devaux C.

AIDS Res Hum Retroviruses. 2015 May;31(5):554-8. doi: 10.1089/AID.2014.0364. Epub 2015 Mar 6.

PMID:
25654164
24.

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.

Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.

J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.

PMID:
25560841
25.

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.

Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.

J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.

PMID:
25560840
26.

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.

Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E, Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R, Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T, Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower E.

J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.

PMID:
25560839
27.

Anti-HIV activity of fucoidans from three brown seaweed species.

Thuy TT, Ly BM, Van TT, Quang NV, Tu HC, Zheng Y, Seguin-Devaux C, Mi B, Ai U.

Carbohydr Polym. 2015 Jan 22;115:122-8. doi: 10.1016/j.carbpol.2014.08.068. Epub 2014 Sep 2.

PMID:
25439876
28.

Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naïve HIV-2-infected patient.

Zheng Y, Lambert C, Arendt V, Seguin-Devaux C.

AIDS. 2014 Sep 24;28(15):2329-31. doi: 10.1097/QAD.0000000000000414. No abstract available.

PMID:
25313590
29.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.

J Clin Microbiol. 2014 Feb;52(2):517-23. doi: 10.1128/JCM.02461-13. Epub 2013 Dec 4.

30.

What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?

Vanham G, Buvé A, Florence E, Seguin-Devaux C, Sáez-Cirión A.

AIDS. 2014 Feb 20;28(4):603-5. doi: 10.1097/QAD.0000000000000147. No abstract available.

31.

Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: validation through agonist and antagonist docking.

Arumugam K, Crouzy S, Chevigne A, Seguin-Devaux C, Schmit JC.

J Biomol Struct Dyn. 2014;32(8):1274-89. doi: 10.1080/07391102.2013.817952. Epub 2013 Jul 22.

PMID:
23869548
32.

HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, Verhofstede C, Lie Y, Seguin-Devaux C, Schmit JC, Bercoff DP.

PLoS One. 2013 May 8;8(5):e60566. doi: 10.1371/journal.pone.0060566. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/7c0b830d-e75d-4128-ab54-7d5ecfd99d19.

33.

Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.

Radloff R, Gras A, Zanger UM, Masquelier C, Arumugam K, Karasi JC, Arendt V, Seguin-Devaux C, Klein K.

Hum Mutat. 2013 May;34(5):725-34. doi: 10.1002/humu.22295. Epub 2013 Mar 11.

PMID:
23418033
34.

Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.

Chalmet K, Dauwe K, Foquet L, Baatz F, Seguin-Devaux C, Van Der Gucht B, Vogelaers D, Vandekerckhove L, Plum J, Verhofstede C.

J Infect Dis. 2012 Jan 15;205(2):174-84. doi: 10.1093/infdis/jir714. Epub 2011 Dec 5.

PMID:
22147802
35.

High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.

Karasi JC, Dziezuk F, Quennery L, Förster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC.

J Clin Virol. 2011 Nov;52(3):181-6. doi: 10.1016/j.jcv.2011.07.002. Epub 2011 Aug 3.

PMID:
21813320
36.

Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.

Gras A, Schneider S, Karasi JC, Ternes AM, Sauvageot N, Karasi-Omes C, Henry AP, Schmit JC, Seguin-Devaux C, Arendt V.

Curr HIV Res. 2011 Jun;9(4):223-8. doi: 10.2174/157016211796320270.

37.

Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.

Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A, Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM.

HIV Med. 2011 Oct;12(9):544-52. doi: 10.1111/j.1468-1293.2011.00922.x. Epub 2011 Apr 25.

38.

C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes.

Hanriot D, Bello G, Ropars A, Seguin-Devaux C, Poitevin G, Grosjean S, Latger-Cannard V, Devaux Y, Zannad F, Regnault V, Lacolley P, Mertes PM, Hess K, Longrois D.

Thromb Haemost. 2008 Mar;99(3):558-69. doi: 10.1160/TH07-06-0410.

PMID:
18327405
39.

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

Roman F, Hawotte K, Struck D, Ternes AM, Servais JY, Arendt V, Hoffman P, Hemmer R, Staub T, Seguin-Devaux C, Schmit JC.

World J Gastroenterol. 2008 Feb 28;14(8):1237-43.

40.

Improvement of donor myocardial function after treatment of autonomic storm during brain death.

Audibert G, Charpentier C, Seguin-Devaux C, Charretier PA, Grégoire H, Devaux Y, Perrier JF, Longrois D, Mertes PM.

Transplantation. 2006 Oct 27;82(8):1031-6.

PMID:
17060850
41.

Retinoic acid amplifies the host immune response to LPS through increased T lymphocytes number and LPS binding protein expression.

Seguin-Devaux C, Hanriot D, Dailloux M, Latger-Cannard V, Zannad F, Mertes PM, Longrois D, Devaux Y.

Mol Cell Endocrinol. 2005 Dec 21;245(1-2):67-76. Epub 2005 Nov 23.

PMID:
16309824
42.

Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.

Gaillard V, Casellas D, Seguin-Devaux C, Schohn H, Dauça M, Atkinson J, Lartaud I.

Hypertension. 2005 Aug;46(2):372-9. Epub 2005 Jun 20.

PMID:
15967870
43.

Dynamics of dendritic cell phenotype and interactions with CD4+ T cells in airway inflammation and tolerance.

Oriss TB, Ostroukhova M, Seguin-Devaux C, Dixon-McCarthy B, Stolz DB, Watkins SC, Pillemer B, Ray P, Ray A.

J Immunol. 2005 Jan 15;174(2):854-63.

44.

Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3.

Ostroukhova M, Seguin-Devaux C, Oriss TB, Dixon-McCarthy B, Yang L, Ameredes BT, Corcoran TE, Ray A.

J Clin Invest. 2004 Jul;114(1):28-38.

45.

Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation.

Chen CH, Seguin-Devaux C, Burke NA, Oriss TB, Watkins SC, Clipstone N, Ray A.

J Exp Med. 2003 Jun 16;197(12):1689-99.

46.

Enhancement of the inducible NO synthase activation by retinoic acid is mimicked by RARalpha agonist in vivo.

Seguin-Devaux C, Devaux Y, Latger-Cannard V, Grosjean S, Rochette-Egly C, Zannad F, Meistelman C, Mertes PM, Longrois D.

Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E525-35.

Supplemental Content

Loading ...
Support Center